articleTop 10% cited
A Randomized Trial of Etanercept as Monotherapy for Psoriasis
Archives of Dermatology · 2003 · Vol. 139(12) · pp. 1627–1627
Abstract
Etanercept monotherapy provided significant benefit to patients with psoriasis and had a favorable safety profile.
Psoriasis: Treatment and PathogenesisDermatology and Skin DiseasesAutoimmune Bullous Skin DiseasesEtanerceptMedicinePsoriasisPlaceboDermatology Life Quality IndexPsoriasis Area and Severity IndexAdverse effectInternal medicineOutpatient clinicRandomized controlled trial
MeSH terms
EtanerceptAdolescentAdultAgedComputer GraphicsDouble-Blind MethodFemaleHumansImmunoglobulin GImmunosuppressive AgentsMaleMiddle AgedPsoriasisRetrospective StudiesReceptors, Tumor Necrosis Factor
Funding
- Amgen
- University of California, Irvine
Citations
469
FWCI
9.38
field-weighted impact
References
11
Percentile
99%
vs. same field & year
Citations per year
Cited by
The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results
British Journal of Dermatology · 2008 · 783 citations
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
British Journal of Dermatology · 2005 · 692 citations
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Journal of the American Academy of Dermatology · 2019 · 880 citations
Guidelines of care for the management of psoriasis and psoriatic arthritis
Journal of the American Academy of Dermatology · 2008 · 765 citations
Guidelines of care for the management of psoriasis and psoriatic arthritis
Journal of the American Academy of Dermatology · 2008 · 1,202 citations
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Journal of the American Academy of Dermatology · 2007 · 872 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.